EMEA-002597-PIP01-19

Key facts

Active substance
Efgartigimod alfa
Therapeutic area
Neurology
Decision number
P/0097/2020
PIP number
EMEA-002597-PIP01-19
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of myasthenia gravis
Route(s) of administration
Intravenous use
Contact for public enquiries
argenx BVBA

E-mail: mvandenhaute@argenx.com
Tel.: +32 93351730

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating